Ramky Infrastructure (NSE: RAMKY) secures Rs 3,000cr Maharashtra pharma park concession, lifting order book to Rs 13,500cr

Ramky Infrastructure Limited (NSE: RAMKY | BSE: 533262), the Hyderabad-headquartered engineering and development group, has executed a concession agreement with the Maharashtra Industrial Development Corporation for the development of a High-Tech Pharmaceutical Park at the Dighi Port Industrial Area in Raigad district. The project, awarded to Maha Integrated Life Sciences City Limited, a wholly owned subsidiary of Ramky Infrastructure Limited, carries a total estimated cost of INR 3,000 crore and spans a concession period of 95 years, including a five-year construction phase. The award adds the construction component to Ramky Infrastructure Limited’s order book, lifting the total to approximately INR 13,500 crore. Shares of Ramky Infrastructure Limited responded positively on the day of disclosure, rising as much as 4.85% to touch an intraday high of INR 489, though the stock remains well below its 52-week high of INR 705.

What does the DBFOT model mean for Ramky Infrastructure Limited’s long-term revenue visibility and balance sheet risk?

The project will be implemented under the Design, Build, Finance, Operate and Transfer model, which means Maha Integrated Life Sciences City Limited carries the full project finance burden during construction and then operates the asset for 90 years before eventual transfer. This structure is fundamentally different from a conventional engineering, procurement and construction contract where a contractor builds to specification and collects payment on milestones. Under DBFOT, the developer takes both the construction execution risk and the long-term occupancy and revenue risk. For Ramky Infrastructure Limited, the attraction is the extended revenue tail: a nine-decade operating period generating lease premiums, development charges, maintenance fees, and utility income from tenants who set up within the park. The INR 3,000 crore project cost figure, notably, includes an estimate of that future operating income, so the upfront capital commitment and the long-term income stream are being presented as a single aggregate rather than separately stated.

The capital intensity of the model raises an important question about financing structure. Ramky Infrastructure Limited has not disclosed the debt-equity mix or whether any government viability gap funding has been arranged. At a current market capitalisation of roughly INR 3,200 crore, a INR 3,000 crore development commitment through a wholly owned subsidiary is not a trivial balance sheet exposure, even if the spending is staged across five construction years. The company will need to demonstrate, over the coming quarters, how Maha Integrated Life Sciences City Limited intends to finance this greenfield development and whether parent-level guarantees are required. Investors should watch for financing disclosures in the annual report and regulatory filings.

Why is Dighi Port Industrial Area in Raigad district strategically important for India’s pharmaceutical manufacturing ambitions?

Location matters considerably in pharmaceutical industrial real estate. Dighi Port Industrial Area spans 6,056 acres in Raigad district and sits adjacent to the upcoming Dighi port, with road access to National Highway 66 within ten kilometres and rail connectivity through the Konkan Railway to the Jawaharlal Nehru Port and the Dedicated Freight Corridor. The site is designed to decongest the Mumbai metropolitan region by offering an alternative industrial corridor connecting both Mumbai and Pune. For pharmaceutical companies evaluating manufacturing locations, proximity to port infrastructure directly affects logistics costs for both active pharmaceutical ingredient imports and finished formulation exports.

The proposed park will cover approximately 1,000 hectares within this zone, spanning Mangaon and Roha talukas. At that scale, the development is large enough to function as a self-contained industrial ecosystem rather than a standard industrial estate. The project envisages industrial zones, commercial areas, research and development incubation hubs, technology transfer platforms, shared utilities, internal road networks, and open spaces. The inclusion of R&D infrastructure alongside manufacturing capacity signals an intention to attract companies seeking to integrate discovery and production on a single campus, a model more commonly associated with dedicated life sciences districts in Europe and the United States rather than conventional Indian industrial parks.

How does this project fit into India’s broader strategy to reduce pharmaceutical supply chain dependence on China?

The timing of this concession is not coincidental. India’s pharmaceutical sector is in the middle of a structural investment cycle driven directly by the China-plus-one diversification push from global drug manufacturers and by domestic policy urgency following supply chain vulnerabilities exposed between 2020 and 2022. Commissioned pharmaceutical projects in India reached INR 67.6 billion in 2023 to 2024 and INR 60.4 billion in 2024 to 2025, compared to a ten-year prior average of roughly INR 21 billion. The Production Linked Incentive scheme for active pharmaceutical ingredients and key starting materials, with an outlay of INR 69.4 billion, has been the central policy lever accelerating this cycle, with actual investment commitments now exceeding originally targeted levels.

The challenge for India’s ambition is a structural one: approximately 70% of India’s API requirements, and up to 90% for critical antibiotics such as cephalosporins and penicillin, are currently sourced from Chinese manufacturers. A large-scale integrated park that co-locates manufacturing, utilities, and R&D infrastructure could reduce that dependency by giving companies the physical environment to vertically integrate production. Maha Integrated Life Sciences City Limited’s stated intent to provide shared facilities and common infrastructure addresses a specific pain point for smaller pharmaceutical companies that cannot justify the capital cost of dedicated utilities on their own. If the park succeeds in attracting a critical mass of tenants, it could function as an API and formulation corridor that genuinely strengthens India’s manufacturing self-sufficiency.

What are the execution risks and competitive dynamics for this 95-year pharmaceutical park concession in Maharashtra?

A 95-year concession sounds ambitious because it is. The execution risks across a project of this scale and duration are significant. The first and most immediate risk is construction delivery within the five-year window. Ramky Infrastructure Limited’s current standalone order book, prior to this project, was INR 8,500 crore as of December 2025. Adding INR 3,000 crore through the subsidiary nearly doubles the project commitments it needs to execute concurrently. The company employs over 2,000 professionals and has a track record in industrial infrastructure, water, wastewater, roads, and urban development, but managing a greenfield pharmaceutical city at 1,000 hectares is a qualitatively different challenge from conventional EPC delivery.

The second risk is occupancy. Industrial parks succeed or fail based on their ability to attract paying tenants. Maharashtra already has established pharmaceutical clusters, and competing industrial zones are emerging across India under various state government incentive frameworks. Maha Integrated Life Sciences City Limited will need to offer genuinely differentiated infrastructure, competitive land lease terms, and reliable utilities to pull pharmaceutical companies away from existing locations. The revenue model depends on land lease premiums, development charges, maintenance fees, and utility charges, all of which are contingent on tenant density and occupancy rates that will not be clear for several years. The environmental clearance and regulatory compliance burden for a development of this scale is also non-trivial and could cause delays that compress the construction timeline.

There is also a governance consideration that deserves attention. Wholly owned subsidiaries executing long-duration public-private partnership assets create structural separation between the operating entity and the listed parent. Investors in Ramky Infrastructure Limited need visibility into how the subsidiary’s financial performance will be consolidated, whether intercompany guarantees or advances will be disclosed transparently, and what the dividend or distribution policy will be over the operation period. The 90-year operating income figure embedded in the INR 3,000 crore cost estimate should be treated with appropriate caution as a discounted projection rather than a committed revenue stream.

How has the market responded to the Ramky Infrastructure Limited concession announcement, and what does the stock price context reveal?

Ramky Infrastructure Limited’s shares gained as much as 4.85% on March 13, 2026, the day of the regulatory disclosure, touching an intraday high of INR 489 before the market absorbed the news. As of recent trading, the stock has been changing hands in the INR 460 to INR 490 range, which places it significantly below the 52-week high of INR 705 reached earlier in the year but comfortably above the 52-week low of approximately INR 402. Over the past six months, the stock has declined roughly 17%, reflecting broader mid-cap infrastructure sector weakness and stock-specific concerns rather than any fundamental deterioration in the company’s project pipeline.

The market reaction to the concession announcement is best described as measured rather than euphoric. A sub-5% move on a project announcement that effectively adds a development commitment nearly equal to the company’s entire market capitalisation suggests investors are pricing in execution risk alongside the strategic opportunity. The price-to-earnings ratio, recently at approximately 14 to 17 times, is not demanding for a company with an INR 13,500 crore order book, but the stock’s recent underperformance relative to the broader infrastructure sector indicates that institutional confidence has been cautious. Whether this concession acts as a re-rating catalyst will depend on early signals from the five-year construction phase, particularly financing disclosure and the first tenant sign-ons.

What does the Ramky Infrastructure and MIDC pharmaceutical city deal signal for India’s industrial park development sector more broadly?

This concession illustrates an accelerating trend in Indian industrial infrastructure: state governments and development authorities are increasingly willing to commit large land parcels and long-duration concessions to private developers capable of building and operating integrated industrial ecosystems rather than just constructing roads and sheds. The Maharashtra Industrial Development Corporation’s decision to structure this as a 95-year DBFOT rather than a conventional land sale or lease reflects a preference for a developer that takes on the long-term management and operational risk of maintaining the park to internationally competitive standards. That is a structurally positive development for specialised infrastructure developers like Ramky Infrastructure Limited.

The broader competitive implications are interesting. Established pharmaceutical industrial parks operated by entities such as MIDC itself, Gujarat Industrial Development Corporation, and private players across Andhra Pradesh and Telangana will watch the Dighi development closely. If Maha Integrated Life Sciences City Limited successfully aggregates global pharmaceutical tenants at scale within its Raigad zone, it creates a competitive pressure on existing parks to upgrade their infrastructure offering. Conversely, if the park struggles to attract tenants, the lesson will reinforce scepticism about whether India’s pharmaceutical manufacturing ambitions require better demand generation incentives rather than more supply-side industrial real estate. The next few years will test both the developer’s execution capability and the market’s appetite for yet another life sciences cluster on a subcontinent that already has several.

Key takeaways: what the Ramky Infrastructure MIDC pharma park concession means for investors, competitors, and the Indian life sciences sector

• Ramky Infrastructure Limited has secured a 95-year DBFOT concession from Maharashtra Industrial Development Corporation through its wholly owned subsidiary Maha Integrated Life Sciences City Limited, adding the construction-phase value to its order book and lifting the total to INR 13,500 crore.
• The INR 3,000 crore project cost estimate includes projected operating income over the 90-year operation period and should not be interpreted as a committed upfront capital outlay; the actual construction capex and its financing structure have not yet been disclosed.
• The 1,000-hectare park at Dighi Port Industrial Area in Raigad benefits from port adjacency, National Highway 66 access, and Konkan Railway connectivity, positioning it as a logistics-efficient pharma manufacturing location for both import and export flows.
• India’s pharmaceutical investment cycle is running at two to three times its historical average following China-plus-one diversification pressure and Production Linked Incentive-driven policy support, giving this park a favourable demand backdrop if it can achieve timely delivery.
• Execution risk is material: Ramky Infrastructure Limited must finance, build, and populate a greenfield pharmaceutical city within five years while managing an existing order book of INR 8,500 crore, placing significant demands on its operational and financial bandwidth.
• The revenue model relies on land lease premiums, development charges, maintenance fees, and utility income, all of which are occupancy-dependent; tenant sign-ons during and after construction will be the critical performance indicators to monitor.
• The stock reacted with a less-than-5% gain despite the scale of the announcement, suggesting investors are factoring in execution risk and financing uncertainty alongside the strategic upside; the 52-week discount to the high of INR 705 implies room for re-rating if early milestones are delivered.
• The DBFOT structure requires Maha Integrated Life Sciences City Limited to operate and maintain the park for 90 years, creating long-duration subsidiary liabilities that investors in the listed parent should track through consolidated balance sheet disclosures.
• Maharashtra Industrial Development Corporation’s willingness to commit a 95-year concession to a private developer signals a broader shift by Indian state development authorities toward delegating long-term industrial asset management to specialised operators.
• If executed successfully, the Dighi park could serve as a template for similar life sciences industrial city concessions in other Indian states, creating a meaningful new asset class within the listed infrastructure developer segment.